Study Of the Safety of Locally Manufactured 123I-metaiodobenzylguanidine(MIBG) in Routine Clinical Use

N/AWithdrawnNCT01912040

Nova Scotia Health Authority

Overview

Assessing 123 Iodine MIBG produced locally for safety while being used in clinical practice to help in patient management decisions.

We will be assessing for adverse reactions of patients injected with locally manufactured 123 Iodine MIBG. With monitoring of blood pressure and heart rate following injection and any potential immediate side effects.

Study Type

OBSERVATIONAL

Conditions

Adrenergic Pathology

Interventions

Administration of 123Iodine MIBGDRUG

Patients will be administered the locally produced 123 Iodine MIBG

Eligibility

Sex: ALLMin age: 1 Month

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with potential Adrenergic pathology Exclusion Criteria: * Pregnant or breast feeding females * Hypersensitivity to MIBG

Locations (1)

Capital District Health Authority

Halifax, Nova Scotia, Canada

Outcomes

Primary Outcomes

Safety profile of the 123Iodine MIBG

Time frame: BP and Heart rate for 24 hours after injection.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.